SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

OXYGENTA PHARMACEUTICAL LIMITE

BSE: 524636 09 Sep 2025
Healthcare
₹ 74
OXYGENTA PHARMACEUTICAL LIMITED specializes in Pharmaceuticals within the Healthcare sector.

OXYGENTA PHARMACEUTICAL LIMITE - Share Price & Details

Market Cap
₹456.0
High /Low
134.0 / 30.0
Stock P/E
NA
Book Value
₹-6.93
Dividend Yield
0.0
ROCE
-33.4
ROE
₹NA
Face Value
10.0
PEG Ratio
NA
EVEBITDA
₹-59.7
Debt
62.2
CMP / FCF
-36.9
Debt to equity
₹NA
NP Ann
-10.3
High price all time
134.0
Piotroski score
₹5.0
Graham Number
NA
No. Eq. Shares
3.7
Net CF
₹0.02
Net profit
-10.3
Price to book value
NA
Interest Coverage
₹-6.91
Low price all time
2.95
Industry PE
33.8
Reserves
₹-62.6
Free Cash Flow
₹-8.67

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.4691.0
Triochem Products Ltd.,NANANANA0
OXYGENTA PHARMACEUTICAL LIMITENANANANA456.0
BROOKS LABORATORIES LTD.257.2926.51255.120.9435214.0
EVEREST ORGANICS LTD.NANANANA39062.8

Peer Comparison Chart


About OXYGENTA PHARMACEUTICAL LIMITE

OXYGENTA PHARMACEUTICAL LIMITED, with Security Code 524636, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Oxygenta Pharmaceutical Faces Technical Shift Amidst Mixed Financial Indicators and Stakeholder Confidence

(02 Sep 2025)
Oxygenta Pharmaceutical has experienced a recent evaluation adjustment, reflecting shifts in its technical indicators. While the stock shows a notable...
Read more →

Oxygenta Pharmaceutical schedules AGM

(29 Aug 2025)
Oxygenta Pharmaceutical announced that the 32th Annual General Meeting(AGM) of the company will be held on 19 September 2025.
Read more →

Oxygenta Pharmaceutical reports standalone net loss of Rs 6.11 crore in the June 2025 quarter

(15 Aug 2025)
Net Loss of Oxygenta Pharmaceutical reported to Rs 6.11 crore in the quarter ended June 2025 as against net loss of Rs 1.36 crore during the previous...
Read more →

Oxygenta Pharmaceutical Limited Announces Company Secretary & Compliance Officer Changes, Effective August 14, 2025

(15 Aug 2025)
Oxygenta Pharmaceutical Limited at its meeting held on August 14, 2025, considered and approved the resignation of Ms. Dolly Mandhan as the...
Read more →

Oxygenta Pharmaceutical Reports Strong Sales Growth Amidst Profitability Challenges in June 2025

(14 Aug 2025)
Oxygenta Pharmaceutical's financial results for the quarter ending June 2025 reveal strong net sales growth of 178.81% year-on-year, totaling Rs 64.60 crore...
Read more →

Oxygenta Pharmaceutical to hold board meeting

(12 Aug 2025)
Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 August 2025. More News. Company Logo.
Read more →

Company Updates